Phase I Safety Study of DMXAA in Refractory Tumors

Status:
Completed

Trial end date:
2004-01-01

Target enrollment:

Participant gender:

This was a phase I study aimed at identifying safe doses of DMXAA (now known as ASA404) to be used in future combination studies with chemotherapy.

Phase 1

Antisoma Research

Vadimezan